We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Biomarkers Evaluate Kidney Injury in Cancer Patients

By LabMedica International staff writers
Posted on 17 Feb 2021
Print article
Image: Histopathology of drug-induced acute interstitial nephritis showing interstitial inflammation with prominent eosinophils and tubulitis (the presence of inflammatory cells within the tubular wall) (Photo courtesy of NephSim).
Image: Histopathology of drug-induced acute interstitial nephritis showing interstitial inflammation with prominent eosinophils and tubulitis (the presence of inflammatory cells within the tubular wall) (Photo courtesy of NephSim).
Immune checkpoint inhibitors (ICI) are monoclonal antibodies that can unleash the immune system by blocking surface molecules that serve as important breaks (or checkpoints) that mediate negative regulation of T cells. ICI have substantially improved the prognosis for patients with a wide range of malignancies.

ICI therapy may induce a variety of immune related adverse events (iRAEs), including nephrotoxicity. The incidence of iRAE in patients receiving ICI can be as high as 85% depending on the target and the use of mono- or combination therapy. The most commonly affected organs are skin, endocrine glands, gastrointestinal tract, lungs and liver.

Nephrologists at the Mayo Clinic (Rochester, MN, USA) carried out a single center, retrospective observational study. They performed a search of the electronic medical records for all patients who had received an ICI and suffered an acute kidney injury (AKI) event between January 2014 and June 2020. There were 37 patients with ICI-AKI and 13 non-ICI AKI referents in the cohort for analysis. Clinical and laboratory features, including serum creatinine (SCr), serum C-reactive protein (CRP) and urine retinol binding protein/ urine creatinine(uRBP/Cr) levels at AKI event were evaluated.

The scientists reported that At time of AKI, SCr, CRP and uRBP/Cr were significantly higher in the ICI-AKI compared to the non-ICI-AKI patients (median [IQR] serum creatinine 2.0 [1.7, 2.9] versus1.5 [1.3, 1.6] mg/dL, serum CRP 54.0 [33.7, 90.0] versus 3.5 [3.0, 7.9] mg/L and urine uRBP/Cr 1,927 [1,174, 46,522] versus 233 [127, 989] mcg/g Cr, respectively). Compared to the referent group, time from ICI initiation to AKI was shorter in the ICI-AKI patients. Among the ICI-AKI group, complete renal recovery occurred in 39% of patients by three months; rechallenge occurred in 16 (43%) of patients, of whom three (19%) had recurrence of AKI. A pattern was observed with eGFR, which decreased in the ICI-AKI group as compared to the non-ICI-AKI at the time of AKI (median 28.9 [16.7, 37.8] versus 40.6 [38.9, 46] mL/min/1.73m2, respectively.

Sandra M. Herrmann, MD, a Nephrologist and the study's senior author, said, “Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.”

The authors concluded that their study provided novel, important data for clinicians regarding the use of biomarkers in the routine evaluation of cause of AKI in patients on ICI therapy. These biomarkers could assist with discriminating ICI-AKI from other causes and may also help aid clinical decision-making related to both management and recurrence. They also described distinguishing clinical characteristics of patients with ICI-AKI, which may help with the diagnosis and possible prevention of ICI-AKI, by reinforcing the strategy of avoidance of acute interstitial nephritis (AIN) associated drugs in this type of patient. The study was published on February 1, 2021 in the journal Kidney International Reports.

Related Links:
Mayo Clinic

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.